生命科学资讯

Cell therapy company hopes to end Tokyo biotech IPO drought with $92M offering

Boehringer axes inhaled gene therapy after viewing cystic fibrosis data

Sanofi points to 'key opportunity' for Teva-partnered IBD in long-term data

Compass guides psychedelic therapy to 2nd pivotal depression win, triggering approval push

Cyrano noses toward pivotal trial after midphase smell loss win

Novocure gets FDA nod for tumor-treating electric fields targeting pancreatic cancer

Gilead’s latest synthetic lethal therapy comes via $1.5B deal with China’s Genhouse

Biopharma funding to experience 'continued, albeit disciplined' recovery in 2026: PitchBook

'It's really a dire time for patients': Biohaven CEO says FDA red tape is blocking access to rare disease treatments

FDA rejects Disc's rare disease drug despite commissioner's voucher

With the FDA's Moderna decision, vaccine makers face increasingly uncertain regulatory environment

FDA clears Encora Therapeutics’ wearable wrist device for essential tremor

What were the biggest clinical trial flops of 2025?

After R&D head exits, Immunocore CEO pairs ambition with caution for growing cancer portfolio

Chutes & Ladders—Sanofi's stunning CEO switch

Integra LifeSciences cuts roles as 65 staffers impacted from Princeton, N.J., site

Moderna R&D spend shrunk 31% in 2025 amid major pipeline reorg

Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans

'When the markets opened, we were ready': Why biotech IPOs are back for 2026

Icon shares plummet after CRO reveals accounting investigation, pulls 2025 guidance